{"refrec":{"BRefID":295896,"RR":"Polastro, L.; Aftimos, P.G.; Awada, A. (2014). Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. Expert Review of Anticancer Therapy 14(6): 649-665. https://dx.doi.org/10.1586/14737140.2014.920693","BEntID":287984,"PublicFlag":1,"CheckedFlag":1,"wosflag":1,"vabbflag":0,"RefStringPartII":". Expert Review of Anticancer Therapy 14(6): 649-665. https://dx.doi.org/10.1586/14737140.2014.920693","DocTypID":8,"DocType":"Journal article","MarineFlag":0,"FreshFlag":0,"BrackishFlag":0,"TerrestrialFlag":0,"Authorstring":"Polastro, L.; Aftimos, P.G.; Awada, A.","OrigTitleTranslFlag":0,"Authorstringtrunc":"Polastro, L.; Aftimos, P.G.; Awada, A.","Englishabstract":"In the new era of precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. Eribulin mesylate, a microtubule-destabilizing agent, is the only classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years. This synthetic analogue of halichondrin B, isolated from the marine sponge Halicondria Okaida', was responsible for prolonging overall survival of heavily pretreated metastatic breast cancer patients in a large Phase III trial. Eribulin is now under clinical development in earlier settings such as the neo-adjuvant and adjuvant settings. Furthermore, its unique mechanism of action and the absence of cross-resistance with taxanes have led to the design of clinical trials in multiple indications: bladder cancer, lung cancer, prostate cancer... The main adverse events are neutropenia, fatigue and peripheral neuropathy.","AbstractOtherLang":null,"BibLvlCode":"AS","StandardTitle":"Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review","OrigTitleLangCode":"en","OrigTitleLangCodeExtended":"eng","OrigTitleLangID":15,"DateLastModified":{"date":"2024-12-10 01:33:17.368041","timezone_type":1,"timezone":"+01:00"},"UserAccessRight":null,"UserAccID":null,"AuthorKeywords":"breast cancer; chemotherapy; eribulin; review; solid tumor","OtherDescriptors":null,"Notes":null,"AnaPub":2014,"MonPub":null,"DateUpdate":"2022-07-12","DateCreate":"2018-05-15","SecASFANote":null,"ConfID":null,"PeerRev":1,"VlizCoreFlag":1,"WoScode":"WOS:000337744700003","VABBcode":null,"OpenAcc":0,"DOI":"10.1586/14737140.2014.920693"},"refs":null,"anarec":{"AnaID":295896,"PubliDate":2014,"Pagination":"649-665","XtraPublOfAnaID":null,"ISBN":null,"Volume":"14","Issue":"6","BRefMon":null,"BRefMonRR":null,"BRefXtra":null,"BRefXtraRR":null,"SerBRefID":268060,"SerRR":"Expert Review of Anticancer Therapy. TAYLOR & FRANCIS LTD: Abingdon. ISSN 1473-7140; e-ISSN 1744-8328","StandardTitleSer":"Expert Review of Anticancer Therapy","ISSN":"1473-7140","AbbrevSer":null,"StandardTitleMon":null,"StartPage":649,"Pages":17,"ToPubliDate":null,"BRefBibLvlCode":"S","SerNotes":null},"monrec":null,"serrec":null,"relations":null,"relationsRev":null,"addrec":null,"othpubs":null,"ownerships":null,"authors":[{"AutName":"Polastro","Firstname":"Laura","Initials":"L.","Affiliation":"Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles","Discriminator":null,"CorporateFlag":0,"BEntID":287984,"AutID":327721,"OrderNr":1,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null},{"AutName":"Aftimos","Firstname":"Philippe","Initials":"P.G.","Affiliation":"Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles","Discriminator":null,"CorporateFlag":0,"BEntID":287984,"AutID":327722,"OrderNr":2,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null},{"AutName":"Awada","Firstname":"Ahmed","Initials":"A.","Affiliation":null,"Discriminator":null,"CorporateFlag":0,"BEntID":287984,"AutID":327723,"OrderNr":3,"DegrID":null,"EditorFlag":0,"CorrespFlag":0,"IllustratorFlag":0,"ReviserFlag":0,"TranslatorFlag":0,"InsAcronym":null,"InsFSN":null,"ORCID":null,"PersID":null,"InsID":null}],"mapdetails":null,"datasets":null,"monographs":null,"monparts":null,"serparts":null,"BEntOpen":null,"BEntPrivate":null,"availability":[{"BInstID":379099,"LibID":36,"BRefID":295896,"EmbargoDate":null,"FullEmbargoDate":null,"PhysMedID":16,"hasOCRd":null,"ShelfLocCode":"379099","RFID":null,"PaidValue":null,"Medium":"Server","Description":"Interne VLIZ documenten","Acronym":"VLIZ","Library":"Vlaams Instituut voor de Zee","DutchTerm":"Non-open access","URL":null,"ClassifID":228,"Classification":"Non-open access","ReqLink":1,"ClassifTypID":3,"URLLocation":"https://www.vliz.be/imisdocs/publications/","SubDir":1,"InternalReq":1,"LoggedInReq":1,"Disclaimer":"Disclaimer_VLIZ_Intern","DutchDisclaimer":"
Deze publicatie is enkel beschikbaar voor persoonlijk gebruik binnen de Innovocean site en mag op geen enkele manier verder worden verspreid.